According to World Health Organisation (WHO), antibiotic resistance is one of the biggest threats to global health. It is linked to 23,000 deaths per year, researchers said.
Paying closer attention to underlying fungal infections is necessary to reduce drug resistance, they said.
"If we are trying to deliver globally on a comprehensive plan to prevent antimicrobial resistance, and we are treating blindly for fungal infections that we do not know are present with antibiotics, then we may inadvertently be creating greater antibiotic resistance," said lead author David Perlin, from Rutgers New Jersey Medical School in the US.
Better training is needed to encourage health care practitioners to test for fungal infections so the correct drugs are administered.
The report cites four common clinical situations in which a lack of routine diagnostic testing for fungal diseases often worsens the problem.
It said many people diagnosed with tuberculosis of the lungs do not have TB - known as smear negative cases - but are treated ineffectively with costly TB drugs.
A simple antibody test can pick up the fungus Aspergillus, which can be treated by antifungal drugs rather than unnecessary anti-TB antibiotics. In 2013, more than 2.7 million smear-negative TB cases were reported to the WHO.
Fungal asthma is often misdiagnosed as chronic obstructive pulmonary disease (COPD) and treated with antibacterial drugs and steroids.
Of more than 200 million asthma sufferers, an estimated 6 million to 15 million have fungal asthma, which can be diagnosed with skin testing or blood tests and responds to antifungal agents, not antibiotics, the report notes.
"Fungal disease diagnostics are critical in the AMR fight and will improve survival from fungal disease across the world," said David Denning from the University of Manchester in the UK.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
